New Approved Drugs Keep Us in the Proverbial Pickle

Over the last year or so we have seen a marked change in the treatment landscape for men with castrate resistant advanced prostate cancer. The FDA has approved sipuleucel-T (Provenge), cabazitaxel (Jevtana) and last week it also approved abiraterone (Zytiga). This changed landscape of multiple treatment options creates new problems, of course good problems. Prostate [...]

Malecare’s Advanced Prostate Cancer Program

Malecare is pleased to announce several new enhancements to our Advanced Prostate Cancer Program as well as the release of our new Advanced Prostate Cancer Kit which includes our newest publication: RECURRENT PROSTATE CANCER A Working Document for Men with Recurrent Prostate Cancer For many years, Malecare has been the leader in the fight against [...]

Finally, A New Phase III Clinical Trial to Open Evaluating TAK-700

Finally, some good news as Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited have announced their intention to start a Phase III clinical trial of TAK-700 in the U.S. for men with advanced prostate cancer. TAK-700, which I have been writing about under the heading of “On the Horizon,” is [...]

On The Horizon – A Status Report of Six New Promising Advancing Treatments for Men with Advanced Prostate Cancer as of the Beginning of June, 2010

As of today there are many different potential drugs undergoing phase III evaluations for men with advanced prostate cancer, some of them seem to offer great hope and promise. Considering we just had Provenge finally approved, this is great news. […]

Go to Top